Affymax, Inc. and Takeda Global Research & Development Center, Inc. Announce FDA Acceptance of New Drug Application for Peginesatide

Published: Jul 27, 2011

PALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematideā„¢) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.

Back to news